Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Crunchfish half-year report 2024 webinar

Crunchfish AB (“Crunchfish”) half-year report 2024 webinar is now available, where Crunchfish CEO Joachim Samuelsson is interviewed by Chief Analyst Martin Dominique from Västra Hamnen Corporate Finance.[Two men sitting at a table Description automatically generated]   The webinar about Crunchfish half-year report for 2024 is now available via the following link: Webinar half-year report    Crunchfish half-year report for 2024 is available via the following link: Crunchfish half-year report 2024 

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

· Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding US.   · Proveca has been granted a non-exclusive option to license Cessatech’s CT002 program. · Proveca is a global pharmaceutical company specialising in the development and licensing of medicines to address the unmet medical needs in children. Proveca is based in Manchester, England.On 26 August – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company has entered into an exclusive commercialization agreement with Proveca Ltd - a global pharmaceutical company

Neola’s CEO to BioStock: “We are now preparing for a clinical study in the US”

After recently receiving a CB certificate for its medical device, intensive work is now underway at Neola Medical to prepare for the clinic. As part of this, a clinical pilot study will be carried out together with a neonatal ward in Sweden. – This is a step to optimize the conditions for a successful clinical study in premature babies in the United States, CEO Hanna Sjöström tells BioStock.Read the full article at biostock.se : https://www.biostock.se/en/2024/08/neolas-ceo-we-are-now-preparing-for-a-clinical-study-in-the-us/ This is a press release

Notification under Chapter 9, Section 10 of the Finnish Securities Market Act

Neste Corporation, Stock Exchange Release, 26 August 2024 at 9:15 a.m. (EET)Neste Corporation has on 23 August 2024 received a notification under Chapter 9, Section 10 of the Finnish Securities Market Act (FSMA). According to the notification by BlackRock, Inc., the aggregate holdings of the entities referred to therein excluding financial instruments according to SMA 9:6a have on 22 August 2024 decreased to below 5% of the total number of shares and voting rights of Neste Corporation. The aggregate holdings including financial instruments according to SMA 9:6a owned by BlackRock, Inc.

Strong improvement of balance sheet by early repayment of debt, positive operating cash flow and continuous positive development in EBITDA in 2024-H1

Company Announcement No. 11 - 20242024-H1 financial report Management commentaryIn 2024-H1, Donkey Republic realized revenues of DKK 59.8M and improved EBITDA by 75% compared to 2023-H1.These results showcase successful strategy execution, with positive operating cash flow underscoring our focus on efficiency and profitability. This positive cash flow allowed for early debt repayment, significantly strengthening our balance sheet. Additionally, in 2024-Q2 we rolled out our operation in Hannover, Germany and commenced the long term B2G contract which was awarded in 2023-Q4. We look

ContextVision publishes Webcast for Q2 2024

Watch CEO Gerald Pötzsch and CFO Richard Hallström present ContextVision’s highlights from Q2 2024 along the financials for the quarter. The Webcast is available on ContextVision’s website following the link below: https://www.contextvision.com/investors/webcast/ For more details, contact ContextVision’s CFO, Richard Hallström at richard.hallstrom@contextvision.com or visit our official website at www.contextvision.com. About ContextVisionContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market

ContextVision AB: Q2 interim report 2024 - Strong cash position supports continued investment in Image and Data Quality

Q2 Highlights · New customers signed in Asia and North America. ContextVision now has potential to expand its footprint in North America in different segments. · Stable cash flow and good cash position enable continued investments in image quality and in data quality. · Progress in Point-of-Care Ultrasound (POCUS) as ContextVision enters early stages of the development of new product pipeline for organ specific applications. · Final stage of signing an advanced development partnership regarding POCUS. Q2 Financial Data · Net Sales of 31.7 MSEK (33.8), down -6.2%. ·

CYBER1 - Great potential in cybersecurity - Mangold Insight Analysis

Mangold updates Cyber Security 1 (“CYBER1”). Revenues increased to EUR 28.7 (25.1) million in the first half of 2024, corresponding to a growth rate of around 15 percent. The revenue was in line with our estimate, which we believe shows that the company is on the right path. The gross margin was 21.0 (22.5) percent, which was slightly lower than estimate. However, personnel costs and other costs were lower than we expected, which means that we will lower the operational costs moving forward. We continue to estimate that CYBER1 will achieve full-year profitability in 2024. Mangold welcomes

Veidekke: Exercise of employee share options in Veidekke ASA

A total of 20 participants in the Company's share option program have on August 23[rd] 2024 exercised a total of 18 775 options at a strike price of NOK 39.46.A total of 50 participants in the Company's share option program have on August 23[rd] 2024 exercised a total of 45 463 options at a strike price of NOK 99.36. Shares acquired through the program have a sales restriction on one year after exercise date.Following the exercise, the employees will purchase 64 238 shares. These shares will be transferred during September.  5 500 options have been exercised by primary insiders.

FDA Grants Fast Track Designation for Bexmarilimab

Faron Pharmaceuticals Ltd.   (“Faron” or the “Company”)     Inside Information: FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS   Company announcement, Inside Information, 26 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST   Key highlights -          Given the strong data seen in Phase 1 and continuing in Phase 2 of Faron’s BEXMAB trial, the FDA has granted Fast Track Designation (FTD) for bexmarilimab for the treatment of r/r MDS -          FTD further strengthens the bexmarilimab program by offering clinical development and commercialization

Stora Enso: Numerous measures launched following the environmental violation in Finland

STORA ENSO OYJ PRESS RELEASE 26 August 2024 at 9:00 EESTAn environmental violation was discovered at a Stora Enso harvesting site on Thursday 15 August, in Kainuu, Finland. The violation is being investigated as a serious nature conservation crime. Hans Sohlström, President and CEO of Stora Enso, says the Company took immediate action as soon as it became aware of the violation: "It is important that the negligence at Hukkajoki river in Kainuu came to light. Even the best rule and the most important principle is worthless if it is not applied in practice. We have already initiated a number

Peab builds offices, stores and parking garage in Malmö

Peab has been commissioned to rebuild and extend the old welding and boiler workshop "Hall 259" in Varvsstaden in Malmö. The customer is Varvsstaden AB and the contract is worth SEK 454 million.The historic building Hall 259 is located in the northwest corner of Varvsstaden along Stora Varvsgatan. The building has a high cultural and historical value and will be largely preserved. Two extensions will also be built adjacent to Hall 259. The upgraded building will consist of a grocery store and a parking garage for about 500 cars on five floors. Offices will be built in the southern

Interim Report, January – June 2024

The figures refer to the Group unless otherwise stated. Figures in parentheses refer to the corresponding period of 2023 unless otherwise stated. SECOND QUARTER 2024 · Revenues increased to SEK 16.4 M (13.6). · Earnings before depreciation and amortization (EBITDA) amounted to SEK -1.5 M (-8.3). · Earnings before interest and taxes (EBIT) amounted to SEK -6.7 M (-13.5). · Bringing loss for the period to SEK -5.2 M (-14.2). · Loss per share -0.1 (-0.4). SIGNIFICANT EVENTS IN THE SECOND QUARTER • Sileon has resolved on a previously communicated rights issue of

Read original

OBSERVE MEDICAL ASA: First half year report 2024

Oslo, August 26, 2024 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the first half of 2024. Business update In the first half of 2024, Observe Medical achieved growth and market expansion of the UnoMeter™ portfolio. Observe Medical has achieved a major milestone with the early commercial launch of the UnoMeter™ Safeti Plus, marking significant strategic and commercial progress. This success highlights the effective collaboration between our product development team and external manufacturing partner. The launch underscores our commitment to

Faroese Strike Impacts Financial Performance, but Strong Operational Metrics

The Bakkafrost Group delivered a total operational EBIT of DKK 388 million (DKK 353 million) in Q2 2024.(Figures in parenthesis refer to the same period last year unless otherwise specified) Faroe Islands:          · Revenues of DKK 1,187 million (1,082 million) · Operational EBIT of DKK 275 million (282 million) Scotland: · Revenues of DKK 880 million (587 million) · Operational EBIT of DKK 113 million (71 million) Commenting on the result, CEO Regin Jacobsen said: "We are not content with the financial performance this quarter, largely due to the strike in the

Lundin Mining Announces Labour Agreement at Caserones Mine

VANCOUVER, BC, Aug. 24, 2024 /CNW/ - (TSX: LUN; Nasdaq Stockholm: LUMI) Lundin Mining Corporation (“Lundin Mining” or the “Company”) is pleased to announce today that an agreement has been reached with the union at Caserones and accepted by the majority of the union members through a vote. Further to the press release dated August 12, 2024 entitled “Lundin Mining Provides Update on Labour Negotiations at its Caserones Mine“ , a new collective bargaining agreement will be signed imminently. The Company

Dooba Finance AB (publ) – Publishing of the Quarter End Report for Q2 2024

On 3 May 2024, Dooba Finance AB (publ) (the “Company”) issued senior unsecured sustainability-linked floating rate bonds in the amount of SEK 600,000,000 under its new framework of up to SEK 800,000,000 senior unsecured sustainability-linked floating rate bonds guaranteed by Dooba Holdings Limited (the “Bonds”).The Company today announces the publication of its Quarter End Report for Q2 2024. The report can be found at https://dfabbond.se/

Panoro Energy ASA - Announces Transactions Made Under the Company’s Share Buyback Program

Oslo, 23 August 2024 – Panoro Energy ASA (“Panoro” or the “Company”) (OSE: PEN) initiated a share buyback program on May 23, 2024 to repurchase up to NOK 100 million in value of the Company’s common shares in open market transactions on the OSE pursuant to an agreement with Arctic Securities AS.   For the period from and including 19 August through 23 August 2024, Panoro purchased a total of 150,000 shares at an average price of NOK 30.3144 per share. The transactions effected through the agreement with Arctic comprise all the transactions effected by or on behalf of the Company

Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis

Lund, Sweden, 23 August 2024. Hansa Biopharma AB, (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US President has decided to leave the company in late September. Effective immediately, the Commercial Leadership team will report to Søren Tulstrup, President and CEO. A search is underway for a new CCO and US President. Matthew Shaulis, CCO and US President, Hansa Biopharma said, “Joining Hansa was a key moment for my career and while the decision to leave was hard, especially given the company’s solid progress, I know

Relais Group Plc: Share Repurchase 23.8.2024

Relais Group Plc  ANNOUNCEMENT  23.8.2024 Relais Group Plc: Share Repurchase 23.8.2024 In the Helsinki Stock Exchange Trade date           23.8.2024Bourse trade         BuyShare                  RELAISAmount             820 SharesAverage price/ share    14,9000 EURTotal cost            12 218,00 EUR Relais Group Plc now holds a total of 48 679 sharesincluding the shares repurchased on 23.8.2024 On behalf of Relais Group Plc Nordea Bank Oyj Janne

There are no items matching the current filter
There are no more items matching the current filter
Back to top